首页> 外文期刊>Psychiatry research >Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms
【24h】

Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms

机译:精神分裂症门诊患者在选择抗精神病药物后出现显着的阴性或杂乱无章的思想症状的可靠性,有效性和检测PANSS阴性症状因子评分变化的能力

获取原文
获取原文并翻译 | 示例
           

摘要

The PANSS is a valid instrument assessing schizophrenia symptom severity. Analyses have identified a five-factor solution. The negative symptom factor (NSFS) is robust, having been replicated in multiple analyses. The score has superior content validity versus the negative subscale. Aspects of validity in patients with predominant negative symptoms have yet to be established. The present data are from a Phase IIb study of add-on bitopertin therapy in schizophrenia outpatients with prominent negative or disorganized thought symptoms treated with antipsychotics. Analyses were conducted to evaluate reliability, validity and sensitivity to change. Test-retest screening to baseline was high (ICC=0.93). This was maintained in-study, for patients with no change in CGI negative symptom severity (CGI-S-N). Internal consistency at baseline was adequate (α=0.71) and increased at later assessments. Pearson correlation at baseline showed a good association between NSFS and CGI-S-N (0.63), but not overall CGI-S (0.31). Association with PSP at baseline was moderate (-0.39) and for change at Week eight good (-0.65). NSFS responders (≥20% improvement) at Week eight showed a significant improvement in function. The analyses demonstrated reliability, validity and ability to detect change of the NSFS, in schizophrenia patients with prominent negative or disorganized thought symptoms.
机译:PANSS是评估精神分裂症症状严重程度的有效工具。分析确定了五因素解决方案。负面症状因素(NSFS)可靠,已在多次分析中复制。该分数具有优于负子量表的内容效度。具有主要阴性症状的患者的有效性方面尚未确定。目前的数据来自IIb期附加Bitopertin疗法的研究,该疗法在精神分裂症门诊患者中使用抗精神病药治疗,具有明显的阴性或精神错乱症状。进行了分析以评估变化的可靠性,有效性和敏感性。重测基线筛查率较高(ICC = 0.93)。对于CGI阴性症状严重程度(CGI-S-N)没有变化的患者,应继续进行研究。基线时的内部一致性足够(α= 0.71),在以后的评估中会增加。基线时的皮尔逊相关性显示NSFS与CGI-S-N(0.63)之间有良好的关联,但对整体CGI-S(0.31)却没有。基线时与PSP的关联为中度(-0.39),第八周的变化为良好(-0.65)。第八周的NSFS应答者(改善≥20%)显示出功能上的显着改善。分析表明,在精神症状严重的阴性或精神错乱的精神分裂症患者中,NSFS的可靠性,有效性和检测能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号